ArticleEuropean journal of medical research2025
Transcriptomic exploration combined with experimental validation: uncovering the potential value of biomarkers related to ammonia-induced cell death in hepatic ischemia-reperfusion injury.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHepatic ischemia-reperfusion injury (HIRI) represents the leading cause of postoperative liver dysfunction and failure. Ammonia-induced cell death (ACD), defined by lysosomal and mitochondrial disruption due to intracellular ammonia accumulation, appears to contribute to the pathogenesis of HIRI.
methodsTranscriptomic datasets GSE151648 and GSE12720 were retrieved from the Gene Expression Omnibus (GEO), and 467 ACD-related genes were compiled from published reports. Differential expression analysis combined with Weighted Gene Co-expression Network Analysis (WGCNA) was applied to identify candidate genes and assess their functional relevance. Biomarkers closely associated with HIRI were subsequently determined through protein-protein interaction (PPI) network construction, machine learning approaches, and expression validation. A nomogram was then established based on these biomarkers, followed by Gene Set Enrichment Analysis (GSEA), immune infiltration profiling, and network prediction. Furthermore, single-cell analysis was employed to investigate the expression of biomarkers across different cell types. Finally, liver tissues from HIRI mouse models were examined to confirm biomarker expression.
resultsA total of 586 differentially expressed genes intersected with 762 key module genes, yielding 39 candidates primarily enriched in inflammatory signaling pathways. Among these, LCP1, SLC16A3, and RGS2 emerged as biomarkers, each markedly upregulated in HIRI samples. The biomarker-based nomogram demonstrated robust diagnostic accuracy. Enrichment analyses indicated that the biomarkers were closely related to immune and metabolic pathways. Consistently, immune cell infiltration and immune functions were elevated in HIRI samples and correlated significantly with biomarker expression. Concurrently, single-cell analysis revealed that all three biomarkers were expressed within mononuclear phagocytes, with their expression levels exhibiting significant differences between the HIRI group and the control group. Moreover, multiple miRNAs and lncRNAs were predicted to interact with the identified biomarkers. Validation in HIRI mouse liver tissues confirmed consistency with transcriptomic findings.
conclusionLCP1, SLC16A3, and RGS2 have been identified as biomarkers of HIRI. The study advances understanding of ACD-related genes signatures in HIRI and provides a foundation for future mechanistic research and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.